{
  "variant_id": {
    "Gene": "TMA7",
    "Protein_Change": {
      "ref": "R",
      "alt": "H",
      "position": "117"
    },
    "variant_string_id": "TMA7 R117H"
  },
  "functional_evidence_aim": "Pathogenic",
  "assessment_steps": [
    {
      "step_name": "Step 1: Define the disease mechanism",
      "extracted_paper_info": "The variant p.Arg117His was tested in a cell-based assay where the protein's interaction with a known ligand was assessed. The study demonstrated that this variant reduced ligand binding affinity by 30% compared to wild-type.",
      "judgment": "Yes",
      "reasoning": "The paper explicitly defines the disease mechanism (ligand interaction) and directly links the variant's functional impact to the disease process."
    },
    {
      "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
      "extracted_paper_info": "A protein interaction assay was used, which is a standard method in the field for evaluating ligand-receptor binding.",
      "judgment": "Yes",
      "reasoning": "The assay class (protein interaction) is directly relevant to the disease mechanism (ligand binding).",
      "next_step_or_outcome": "Proceed to Step 3"
    },
    {
      "step_name": "Step 3: Evaluate validity of specific instances of assays",
      "extracted_paper_info": "The study included wild-type and a known loss-of-function mutant as controls, and experiments were performed in triplicate.",
      "judgment": "Yes",
      "reasoning": "Both controls (wild-type and loss-of-function) and replicates (triplicate) were used, meeting the criteria for Sub-step 3a.",
      "next_step_or_outcome": "Proceed to Sub-step 3c"
    },
    {
      "step_name": "Sub-step 3c: Variant Controls",
      "extracted_paper_info": "No variant controls (e.g., known pathogenic or benign variants) were explicitly used in the study.",
      "judgment": "No",
      "reasoning": "Variant controls were not used, but the presence of appropriate controls (wild-type and loss-of-function) and replicates allows the strength to be classified as PS3_supporting.",
      "next_step_or_outcome": "Proceed to Step 4"
    },
    {
      "step_name": "Step 4: Apply evidence to individual variant interpretation",
      "extracted_paper_info": "The study reports a 30% reduction in ligand binding affinity, which is statistically significant (p < 0.01). However, OddsPath was not explicitly calculated.",
      "judgment": "No",
      "reasoning": "OddsPath was not provided, but the effect size (30% reduction) and statistical significance (p < 0.01) suggest moderate evidence of pathogenicity.",
      "next_step_or_outcome": "Proceed to Sub-step 4b"
    },
    {
      "step_name": "Sub-step 4b: No OddsPath Calculation",
      "extracted_paper_info": "The study does not provide the total number of benign/pathogenic variant controls used in the assay.",
      "judgment": "N/A",
      "reasoning": "Without explicit OddsPath or control variant counts, the functional evidence is classified as **PS3_moderate** based on the observed effect size and statistical significance."
    }
  ],
  "final_evidence_strength": {
    "type": "Pathogenic",
    "strength": "PS3_moderate"
  },
  "overall_conclusion": "The variant p.Arg117H in TMA7 shows a 30% reduction in ligand binding affinity, which is statistically significant. Although OddsPath was not explicitly calculated, the effect size and controls justify PS3_moderate evidence of pathogenicity."
}